19 min listen
ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: ISCHEMIA-EXTENDed – Follow-Up Interim Report
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
12 minutes
Released:
Apr 4, 2023
Format:
Podcast episode
Description
In this interim report of extended follow-up of ISCHEMIA, with a total of 557 deaths (nearly twice the number of deaths in the initial phase), the probability of a survival benefit at 7 years with either initial management strategy was not different. These findings provide important evidence for patients with chronic coronary disease and their physicians as they decide whether to add invasive management to guideline-directed medical therapy. In this interview, Judith S. Hochman, MD, FACC, FAHA, William E. Boden MD, FACC, FAHA, and Purvi Parwani MBBS, MPH, FACC, discuss ISCHEMIA-EXTENDed – the Follow-Up Interim Report. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Apr 4, 2023
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research